Bedaquiline 200 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Leprosy, MultibacillaryTuberculosisTuberculosis, Multidrug-ResistantTuberculosis, Pulmonary

Phase 2

A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy

CompletedNCT03384641

Janssen Research & Development, LLCLeprosy, Multibacillary

Start: 2018-09-26End: 2024-01-09Updated: 2024-02-02

Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruitingNCT05007821

National Institute of Allergy and Infectious Diseases (NIAID)Tuberculosis, Tuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary

Start: 2022-08-11End: 2026-03-13Updated: 2025-08-12

Related Papers

Bedaquiline Monotherapy for Multibacillary Leprosy

New England Journal of Medicine2024-12-118 citations

Safety of single-dose bedaquiline combined with rifampicin for leprosy post-exposure prophylaxis: A Phase 2 randomized non-inferiority trial in the Comoros Islands

PLoS Medicine2024-10-212 citations